Cargando…

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers

Neisseria meningitidis is a Gram-negative pathogen that actively invades its human host and leads to the development of life-threatening pathologies. One of the leading causes of death in the world, N. meningitidis can be responsible for nearly 1,000 new infections per 100,000 subjects during an epi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esposito, Susanna, Tagliabue, Claudia, Bosis, Samantha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553319/ https://www.ncbi.nlm.nih.gov/pubmed/26351647 http://dx.doi.org/10.1155/2015/402381

Ejemplares similares

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
por: Ruiz García, Yara, et al.
Publicado: (2021)

Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States
por: Banzhoff, Angelika
Publicado: (2017)

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
por: O’Ryan, Miguel, et al.
Publicado: (2013)

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
por: Simões, Maria João, et al.
Publicado: (2017)

Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
por: Bodini, Margherita, et al.
Publicado: (2020)

Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
por: Abitbol, Véronique, et al.
Publicado: (2023)

Fever-Associated Supraventricular Tachycardia after 4CMenB Vaccination in an Infant
por: Gönüllü, Erdem, et al.
Publicado: (2019)

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules
por: Biolchi, Alessia, et al.
Publicado: (2019)

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
por: Marshall, Helen S., et al.
Publicado: (2021)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

Characterization of meningococcal carriage isolates from Greece by whole genome sequencing: Implications for 4CMenB vaccine implementation
por: Kesanopoulos, Konstantinos, et al.
Publicado: (2018)

Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
por: Scholz, Stefan, et al.
Publicado: (2021)

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents
por: Biolchi, Alessia, et al.
Publicado: (2020)

Does social deprivation correlate with meningococcal MenACWY, Hib/MenC and 4CMenB/Meningococcal Group B vaccine uptake in Northern Ireland?
por: Brennan, Orlaith C., et al.
Publicado: (2022)

Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022
por: Rodrigues, C. M. C., et al.
Publicado: (2023)

Correction to: Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease
por: Scholz, Stefan, et al.
Publicado: (2022)

Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile
por: Graña, María Gabriela, et al.
Publicado: (2021)

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
por: Leduc, Isabelle, et al.
Publicado: (2020)

A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model
por: Argante, Lorenzo, et al.
Publicado: (2021)

Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries
por: Abad, Raquel, et al.
Publicado: (2016)

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans
por: Viviani, Viola, et al.
Publicado: (2023)

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp
por: Veggi, Daniele, et al.
Publicado: (2020)

7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains
por: Biolchi, Alessia, et al.
Publicado: (2020)

Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Neisseria meningitidis Strains and Their Predicted Coverage by the 4CMenB Vaccine
por: Tsang, Raymond S. W., et al.
Publicado: (2020)

Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
por: Martinón-Torres, Federico, et al.
Publicado: (2019)

Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage
por: Sereikaitė, Emilija, et al.
Publicado: (2023)

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
por: Zafack, Joseline Guetsop, et al.
Publicado: (2019)

An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol
por: Marshall, Helen S., et al.
Publicado: (2022)

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy
por: Fazio, Cecilia, et al.
Publicado: (2021)

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269
por: Stella, Maria, et al.
Publicado: (2019)

High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS
por: Tozer, Sarah J., et al.
Publicado: (2021)

B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidis
por: Marshall, Helen S, et al.
Publicado: (2019)

02. Beyond B Antigen Coverage: The Potential of the 4CMenB Vaccine for Cross-protection Against Pathogenic Neisseria Infections
por: Garcia, Yara Ruiz, et al.
Publicado: (2021)

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component
por: Sheerin, Dylan, et al.
Publicado: (2019)

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)
por: Azzari, Chiara, et al.
Publicado: (2020)

An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol
por: Thng, Caroline, et al.
Publicado: (2023)

The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study
por: Looker, Katharine J., et al.
Publicado: (2023)

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland
por: Mulhall, Robert M., et al.
Publicado: (2018)

Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults
por: Nolan, Terry, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5of7g5i6nrks6t9a2vdq0cmvnq